60. 再生不良性貧血 Aplastic anemia Clinical trials / Disease details
臨床試験数 : 235 / 薬物数 : 381 - (DrugBank : 83) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 160
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-JapicCTI-194962 | 03/12/2019 | 18/09/2019 | A Phase 2/3 Study of AMG531 in Patients with Aplastic Anemia | A Phase 2/3 Study of AMG531 Combined with Ciclosporin A in Patients with Aplastic Anemia Previously Untreated with Immunosuppressive Therapy | Aplastic Anemia | Intervention name : AMG531 INN of the intervention : romiplostim Dosage And administration of the intervention : SC-administered Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : - | Kyowa Kirin Co., Ltd | NULL | complete | 20 | BOTH | 24 | Phase 2-3 | Japan, Asia except Japan | |
| 2 | NCT04095936 (ClinicalTrials.gov) | December 3, 2019 | 18/9/2019 | Study of AMG531 (Romiplostim) in Patients With Aplastic Anemia | A Phase 2/3 Study of AMG531 Combined With Ciclosporin A in Patients With Aplastic Anemia Previously Untreated With Immunosuppressive Therapy | Aplastic Anemia | Drug: Romiplostim | Kyowa Kirin Co., Ltd. | NULL | Active, not recruiting | 20 Years | N/A | All | 24 | Phase 2/Phase 3 | Japan |
| 3 | NCT03957694 (ClinicalTrials.gov) | April 25, 2019 | 9/5/2019 | Study of AMG531(Romiplostim) in Patients With Aplastic Anemia | A Phase 2/3 Study of AMG531 in Patients With Aplastic Anemia PreviouslyUntreated With Immunosuppressive Therapy | Aplastic Anemia | Drug: Romiplostim | Kyowa Kirin Co., Ltd. | NULL | Active, not recruiting | 20 Years | N/A | All | 14 | Phase 2/Phase 3 | Japan |
| 4 | JPRN-JapicCTI-194746 | 01/2/2019 | 09/05/2019 | A Phase 2/3 Study of AMG531 in Patients with Aplastic Anemia | A Phase 2/3 Study of AMG531 in Patients with Aplastic Anemia Previously Untreated with Immunosuppressive Therapy | Aplastic Anemia | Intervention name : AMG531 INN of the intervention : romiplostim Dosage And administration of the intervention : SC-administered Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : - | Kyowa Kirin Co., Ltd | NULL | complete | 20 | BOTH | 14 | Phase 2-3 | Japan, Asia except Japan | |
| 5 | NCT02773290 (ClinicalTrials.gov) | May 2016 | 9/5/2016 | Study of Romiplostim(AMG531) in Subjects With Aplastic Anemia | Phase 2/3 Study of Romiplostim(AMG531) in Subjects With Aplastic Anemia Refractory to or Ineligible for Immunosuppressive Therapy | Aplastic Anemia | Biological: Romiplostim | Kyowa Kirin Co., Ltd. | NULL | Completed | 20 Years | N/A | All | 46 | Phase 2/Phase 3 | Japan;Korea, Republic of |
| 6 | JPRN-JapicCTI-163243 | 01/2/2016 | 02/05/2016 | Phase 2/3 Study of AMG531 in Subjects with Aplastic Anemia | Phase 2/3 Study of AMG531 in Subjects with Aplastic Anemia Refractory to or Ineligible for Immunosuppressive Therapy | Aplastic Anemia | Intervention name : AMG531 INN of the intervention : Romiplostim Dosage And administration of the intervention : Subcutaneous administration | Kyowa Hakko Kirin Co., Ltd. | NULL | complete | 20 | BOTH | 46 | Phase 2-3 | NULL | |
| 7 | NCT02094417 (ClinicalTrials.gov) | April 14, 2014 | 18/3/2014 | A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia | A Phase 2, Randomized, Open-Label, Parallel, Comparative, Dose-Finding Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia Subjects With Thrombocytopenia Refractory to Immunosuppressive Therapy | Aplastic Anemia | Drug: AMG531 | Kyowa Kirin Korea Co., Ltd. | NULL | Completed | 19 Years | N/A | All | 35 | Phase 2 | Korea, Republic of |